Sheet 1 of 2

INFORM	ATION DISCLOSURE
	CITATION
40	
₹\	
l 100c	

everal sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

10/584,470

604-781

CHIBBER FILING DATE

GROUP

June 22, 2006

Unassigned

U.S. F	PATEN	IT DOC	UMENTS
--------	-------	--------	--------

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING	
INITIAL	5,684,134	11/1997	Fukuda et al	20000000000000000000000000000000000000	SOBCLASS	IF AFERC	ZF DIA I L
	6,593,301	07/2003	Ma et al	200000000000000000000000000000000000000			
	0,000,001	 	REIGN PATENT DOCUMENTS				
		101	ILIGIT PATEINT BOCOMENTS			TRANSI	ATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	0 251 197 A2	01/1988	EP	00000000000	000000000000000000000000000000000000000		
	2 027 434 C1	01/1995	Russian Federation	20000000000	000000000000000000000000000000000000000		X
	WO 95/17182 A1	06/1995	WO	2000000000	000000000000000000000000000000000000000		
	WO 95/35294 A1	12/1995	WO	***************************************	***************************************		
	WO 97/47298 A1	12/1997	WO	00000000000	000000000000000000000000000000000000000		
	WO 00/31109 A1	06/2000	WO	000000000	00000000000000000000000000000000000000		
	WO 03/070261 A1	08/2003	WO	2000000000	200000000000000000000000000000000000000		
	WO 2004/062675 A1	07/2004	WO	000000000	000000000000000000000000000000000000000		
	WO 2004/064852 A1	08/2004	WO	90000000	00000005555555000000	ì	
	WO 2004/093662 A2	11/2004	WO	200000000	000000000000000000000000000000000000000		
	WO 2005/060977 A1	07/2005	WO	**********	***************************************		
	OTHER DOCU	JMENTS (ir	ncluding Author, Title, Date, Pertinen	it pages, e	tc.)		
	Co-Pending U.S. Applic	ation Serial	No. 11/472,554, filed June 22, 2006.				
	Co-Pending U.S. Applic	ation Serial	No. 11/481,255, filed July 6, 2006.				
	Co-Pending U.S. Application Serial No. 11/481,256, filed July 6, 2006.						
	Chibber, R., et al; "Activity of the Glycosylating Enzyme, Core 2 G1cNAc (β1,6) Transferase, is Higher in						
	Polymorphonuclear Leul 49; pp. 1724-1730 (2000	*	n Diabetic Patients Compared With Age-M	fatched Cont	trol Subjects'	'; Diabete	₂s; Vol.
	Chibber, R., et al; "Protein Kinase C β2-Dependent Phosphorylation of Core 2 GlcNAc-T Promotes Leukocyte-						
	Endothelial Cell Adhesion"; Diabeties; Vol. 52; pp. 1519-1527 (2003).						
	Ellies, L.G., et al; "Core 2 Oligosaccharide Biosynthesis Distingjishes between Selectin Ligands Essential for Leukocyte						
	Homing and Inflammation"; Immunity; Vol. 9, pp. 881-890 (1998).						
	Goekjian, P.G., et al; "Protein kinase C inhibitors as novel anticancer drugs"; Expert Opin. Investig. Drugs; Vol. 10, No.						
	12; pp. 2117-2140 (2001). Hartung, Hans-Peter, MD; et al; "Circulating Adhesion Molecules and Tumor Necrosis Factor Receptor in Multiple						
	Sclerosis: Correlation with Magnetic Resonance Imaging"; Annals of Neurology; Vol. 38, No. 2; pp. 186-193 (1995).						
	Hindsgaul, O., et al; "Evaluation of Deoxygenated Oligosaccharide Acceptor Analogs as Specific Inhibitors of						
	Glycosyltransferases"; <i>The Journal of Biological Chemistry</i> ; Vol. 266, No. 27; pp. 17858-17862 (1991).						
	Joshi, J., et al; "Chemistry of Ayurvedic Crude Drugs: Part VIIIa-Shatavari-2: Structure Elucidation of Bioactive						
	Shatavarin-I & other Glycosides ^{b.c.} ; <i>Indian Journal of Chemistry</i> ; Vol. 27B; pp. 12-16 (1988).						
	Kim, S.Y., et al; "Inhibition of Mouse Ear Edema by Steroidal and Triterpenoid Saponins"; Arch Pharm Res.; Vol. 22,						
	No. 3, pp. 313-316 (1999)						
	Kuhns, W., et al; "Processing O-glycan core 1, Galβ1-3GalNAcα-R. Specificities of core 2, UDP-G1cNAc: Galβ1-						
	3Ga1NAc-R(G1cNAc to Ga1NAc) β6-N-acetylglucosaminyltransferase and CMP-sialic acid: Galβ1-3GalNAc-R α3-						
	sialyltransferase"; Glycoconjugate Journal; Vol. 10; pp. 381-394 (1993).						

/Patrick Lewis/ (02/19/2009)					
*Examiner	_	Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; drawin line through citation if not in conformance and not considered. Initial this form with next communication to application.					

INF	ORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.
	CITATION	604-781	10/584,470
		APPLICANT	
		CHIBBER	
	(Use several sheets if necessary)	FILING DATE	TC/A.U.
		June 22, 2006	Unassigned
	Indomethacin-Induced Ga		om Paris polyphylla var. yunnanensis on Ethanol- or ctural Requirement for Activity and Mode of Action"; -1106 (2003).
	Orlacchio, A., et al; "Acti		saminyltransferase in lymphomonocytes from multiple
	Toki, D., et al; "Inhibition acetylglucosaminyltransfe	of UDP-G1cNAc:Ga1β1-3Ga1NA	c-R (G1cNAc to Ga1NAc) β6-N- cells by photoreactive nitrophenyl substrate derivatives";
	Washington, R., et al; "Ex	pression of Immunologically Relev	ant Endothelial Cell Activation Antigens on Isolated Centra elerosis"; Ann. Neurol; Vol. 35, No. 1; pp. 89-97 (1994).
	Li, Cheng-Ming, et al; "Development of monoclonal antibodies against bovine mucin core 2 β6 N-acetylglucosaminyltransferase"; Glycoconjugate Journal; Vol. 16; pp. 555-562 (1999).		

*Examiner

/Patrick Lewis/ (02/19/2009)

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CHIBBER

Atty. Ref.: LCM-604-781

Serial No. 10/584,470

TC/A.U.: Unassigned

Filed: June 22, 2006

Examiner: Unassigned

For: CORE 2 GLCNAC-T INHIBITORS

February 9, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO/SB/08a as filed in co-pending Application Serial No. 11/472,554.

This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

Bv:

∕No. 29,009

LCM:Iff

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000

Facsimile: (703) 816-4100